Nanobiotix S.A (NANO) - Total Liabilities
Based on the latest financial reports, Nanobiotix S.A (NANO) has total liabilities worth €114.13 Million EUR (≈ $133.43 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nanobiotix S.A - Total Liabilities Trend (2011–2024)
This chart illustrates how Nanobiotix S.A's total liabilities have evolved over time, based on quarterly financial data. See NANO working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Nanobiotix S.A Competitors by Total Liabilities
The table below lists competitors of Nanobiotix S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mota-Engil SGPS S.A
LS:EGL
|
Portugal | €7.56 Billion |
|
Formula
TA:FORTY
|
Israel | ILA1.81 Billion |
|
Eastcompeace Technology Co Ltd
SHE:002017
|
China | CN¥1.19 Billion |
|
China Yuchai International Limited
F:CYD
|
Germany | €19.06 Billion |
|
STAAR Surgical Company
NASDAQ:STAA
|
USA | $117.44 Million |
|
Shaanxi Zhongtian Rocket Technology
SHE:003009
|
China | CN¥1.44 Billion |
|
Gree Real Estate Co Ltd
SHG:600185
|
China | CN¥12.80 Billion |
|
Navigator Holdings Ltd
NYSE:NVGS
|
USA | $1.03 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Nanobiotix S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Nanobiotix S.A.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.38 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanobiotix S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanobiotix S.A (2011–2024)
The table below shows the annual total liabilities of Nanobiotix S.A from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €133.12 Million ≈ $155.63 Million |
+39.04% |
| 2023-12-31 | €95.74 Million ≈ $111.93 Million |
+10.28% |
| 2022-12-31 | €86.81 Million ≈ $101.49 Million |
+15.78% |
| 2021-12-31 | €74.98 Million ≈ $87.66 Million |
+17.96% |
| 2020-12-31 | €63.56 Million ≈ $74.31 Million |
+9.38% |
| 2019-12-31 | €58.11 Million ≈ $67.94 Million |
+81.88% |
| 2018-12-31 | €31.95 Million ≈ $37.36 Million |
+135.90% |
| 2017-12-31 | €13.54 Million ≈ $15.84 Million |
+4.16% |
| 2016-12-31 | €13.00 Million ≈ $15.20 Million |
+20.33% |
| 2015-12-31 | €10.81 Million ≈ $12.63 Million |
+60.38% |
| 2014-12-31 | €6.74 Million ≈ $7.88 Million |
+58.29% |
| 2013-12-31 | €4.26 Million ≈ $4.98 Million |
+27.93% |
| 2012-12-31 | €3.33 Million ≈ $3.89 Million |
+67.40% |
| 2011-12-31 | €1.99 Million ≈ $2.32 Million |
-- |
About Nanobiotix S.A
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more